Real-world clinical effectiveness and exploratory longitudinal immunological changes of Efgartigimod in myasthenia gravis: a retrospective study and a single-cell analysis in one patient
Oct 2026· Frontiers in Neurology· Vol 17· 0 citations· 60 references
Medicine
TL;DR
The clinical cohort findings support the effectiveness and favorable safety profile of Efgartigimod in routine practice, and exploratory single-cell and immune repertoire analyses from one patient provide preliminary insights into potential immunological changes beyond IgG reduction.
Abstract
Introduction Efgartigimod, an antagonist of the neonatal Fc receptor, has demonstrated efficacy in generalized myasthenia gravis, but evidence from routine clinical practice remains limited, and its immunological effects beyond immunoglobulin G reduction are incompletely understood. Methods We retrospectively evaluated the 12-week effectiveness and safety of Efgartigimod in 21 patients with acetylcholine receptor antibody-positive generalized myasthenia gravis. Outcomes included changes in Myasthenia Gravis Activities of Daily Living scores, response rates defined by reductions of ≥2 and ≥5 points, achievement of minimal symptom expression, changes in prednisone dosage, and adverse events. To explore potential longer-term immune changes, paired peripheral blood mononuclear cell samples obtained from one patient at baseline and after 6 months of repeated treatment were analyzed using single-cell RNA sequencing and T- and B-cell receptor repertoire sequencing. Results The median MG-ADL score decreased from 7.0 (IQR, 6.0–8.0) at baseline to 1.0 (IQR, 1.0–1.5) at week 12. After the first and second treatment cycles, 85.7 and 94.7% of patients achieved CMI, respectively, while 57.1 and 84.2% achieved ≥5-point reductions. At week 12, 73.7% of patients achieved MSE. Treatment was generally well tolerated, with two mild adverse events and no serious adverse events. Exploratory longitudinal profiling in one patient identified reduced myeloid inflammatory activity and antigen-presentation signatures, attenuated predicted inflammatory intercellular communication, and a more dispersed pattern of T- and B-cell clonal expansion after prolonged treatment. Conclusion The clinical cohort findings support the effectiveness and favorable safety profile of Efgartigimod in routine practice. The exploratory single-cell and immune repertoire analyses from one patient provide preliminary insights into potential immunological changes beyond IgG reduction and require validation in larger cohorts.
Background: Efgartigimod is a human immunoglobulin G1 (IgG1) antibody Fc-fragment that reduces total and pathogenic IgG autoantibody levels through neonatal Fc receptor blockade. ADAPT was a 26-week, global, multicenter, randomized, placebo-controlled, phase 3 trial evaluating efgartigimod in participants with generali...
Filippo Rocca, James F. Howard, M. Pasnoor et al.· ANPAbstract_CBN26· 0 citations
ABSTRACT Introduction Ocular myasthenia gravis (OMG) is an autoantibody‐mediated disease characterized by extraocular muscle weakness. Telitacicept has shown potential in treating autoimmune diseases, but its efficacy and corticosteroid‐tapering outcomes in OMG remain unexamined. Methods This retrospective, multicenter...
Si-Yu Xie, Wen-Li Song, Ran Guo et al.· Brain and Behavior· 0 citations
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating muscle weakness. Double‐filtration plasmapheresis (DFPP) and efgartigimod are commonly used therapeutic strategies for patients with generalized MG (gMG). This single‐center retrospective study aimed to evaluate and compare the...
Jing-Wen Li, W. Wan, Jun Wu et al.· Journal of clinical apheresi...· 0 citations
Mepolizumab provided sustained long-term disease control with low glucocorticoid exposure in FIP1L1::PDGFRA-negative HES and EoLDAS offers a pragmatic measure of longitudinal disease control that warrants prospective validation and may inform future treat-to-target strategies.
K. Chevalier, François Barde, S. Faguer et al.· Journal of Allergy and Clini...· 0 citations
INTRODUCTION
Generalized myasthenia gravis (gMG) is an autoimmune disorder often associated with anti-acetylcholine receptor antibodies (AChR-Abs). Identifying short-term predictors or indicators of clinical improvement is crucial for optimizing treatment strategies.
METHODS
This post hoc analysis utilized data from...
Zhi-Jun Li, Q. Ke, Jian-Ying Xi et al.· Neurological Therapeutics· 0 citations
INTRODUCTION
Efgartigimod, a human immunoglobulin G1 Fc fragment targeting the neonatal Fc receptor, improves symptoms in generalized myasthenia gravis (gMG). It remains unknown whether minimal manifestation (MM) status achieved with efgartigimod can be durably maintained over the long term, and whether subcutaneous (S...
Tetsutada Suzuki, M. Fujimaki, Kota Igari et al.· Neurological Therapeutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.